Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	growth factor binding	GLG1 EPHA3 EPHA5 COL1A1 VEGFA	1.44e-04	156	64	5	GO:0019838
GeneOntologyMolecularFunction	GPI-linked ephrin receptor activity	EPHA3 EPHA5	2.10e-04	7	64	2	GO:0005004
GeneOntologyMolecularFunction	olfactory receptor activity	OR4K17 OR4S2 OR6C2 OR52E6 OR4C46 OR4B1 OR8G2P	4.47e-04	431	64	7	GO:0004984
GeneOntologyBiologicalProcess	embryonic hemopoiesis	STK3 STK4 ATF4 VEGFA	2.66e-06	32	63	4	GO:0035162
GeneOntologyBiologicalProcess	primitive hemopoiesis	STK3 STK4 VEGFA	5.86e-06	12	63	3	GO:0060215
GeneOntologyBiologicalProcess	regulation of adherens junction organization	PTPN23 VEGFA	9.13e-05	5	63	2	GO:1903391
GeneOntologyBiologicalProcess	regulation of cell differentiation involved in embryonic placenta development	STK3 STK4	9.13e-05	5	63	2	GO:0060800
MousePheno	increased growth rate	SOCS2 COL1A1 ITPR3	2.14e-05	15	52	3	MP:0002865
Domain	Mst1_SARAH_domain	STK3 STK4	1.16e-05	2	64	2	IPR024205
Domain	Mst1_SARAH	STK3 STK4	1.16e-05	2	64	2	PF11629
Domain	BET	BRDT BRD3	6.90e-05	4	64	2	PF17035
Domain	NET_dom	BRDT BRD3	6.90e-05	4	64	2	IPR027353
Domain	NET	BRDT BRD3	6.90e-05	4	64	2	PS51525
Domain	Olfact_rcpt	OR4K17 OR4S2 OR6C2 OR52E6 OR4C46 OR4B1 OR8G2P	3.83e-04	393	64	7	IPR000725
Domain	SARAH	STK3 STK4	4.10e-04	9	64	2	PS50951
Domain	SARAH_dom	STK3 STK4	4.10e-04	9	64	2	IPR011524
Domain	RECEPTOR_TYR_KIN_V_2	EPHA3 EPHA5	1.02e-03	14	64	2	PS00791
Domain	RECEPTOR_TYR_KIN_V_1	EPHA3 EPHA5	1.02e-03	14	64	2	PS00790
Domain	Eph_TM	EPHA3 EPHA5	1.02e-03	14	64	2	IPR027936
Domain	Tyr_kinase_rcpt_V_CS	EPHA3 EPHA5	1.02e-03	14	64	2	IPR001426
Domain	EPH_lbd	EPHA3 EPHA5	1.02e-03	14	64	2	SM00615
Domain	Ephrin_lbd	EPHA3 EPHA5	1.02e-03	14	64	2	PF01404
Domain	EphA2_TM	EPHA3 EPHA5	1.02e-03	14	64	2	PF14575
Domain	Tyr_kinase_ephrin_rcpt	EPHA3 EPHA5	1.02e-03	14	64	2	IPR016257
Domain	Ephrin_rcpt_lig-bd_dom	EPHA3 EPHA5	1.02e-03	14	64	2	IPR001090
Domain	EPH_LBD	EPHA3 EPHA5	1.02e-03	14	64	2	PS51550
Domain	Protein_kinase_ATP_BS	STK3 STK4 MET MAP3K5 EPHA3 EPHA5	1.87e-03	379	64	6	IPR017441
Domain	Ephrin_rec_like	EPHA3 EPHA5	3.30e-03	25	64	2	SM01411
Domain	Tyr-kin_ephrin_A/B_rcpt-like	EPHA3 EPHA5	3.30e-03	25	64	2	IPR011641
Domain	TyrKc	MET EPHA3 EPHA5	3.42e-03	88	64	3	SM00219
Domain	Tyr_kinase_cat_dom	MET EPHA3 EPHA5	3.42e-03	88	64	3	IPR020635
Domain	Bromodomain_CS	BRDT BRD3	3.56e-03	26	64	2	IPR018359
Domain	PROTEIN_KINASE_TYR	MET EPHA3 EPHA5	4.50e-03	97	64	3	PS00109
Domain	Tyr_kinase_AS	MET EPHA3 EPHA5	4.50e-03	97	64	3	IPR008266
Domain	PROTEIN_KINASE_ATP	STK3 STK4 MET MAP3K5 EPHA3 EPHA5	4.80e-03	459	64	6	PS00107
Domain	bZIP_1	BACH2 ATF4	6.04e-03	34	64	2	PF00170
Domain	ARM-type_fold	KIFAP3 IPO7 UTP20 UNC79 EIF3M	6.08e-03	339	64	5	IPR016024
Domain	Prot_kinase_dom	STK3 STK4 MET MAP3K5 EPHA3 EPHA5	6.50e-03	489	64	6	IPR000719
Domain	PROTEIN_KINASE_DOM	STK3 STK4 MET MAP3K5 EPHA3 EPHA5	6.75e-03	493	64	6	PS50011
Domain	PTPc	PTPRB PTPN23	6.76e-03	36	64	2	SM00194
Domain	BROMODOMAIN_1	BRDT BRD3	7.13e-03	37	64	2	PS00633
Domain	Bromodomain	BRDT BRD3	7.51e-03	38	64	2	PF00439
Domain	SAM/pointed	MAP3K5 EPHA3 EPHA5	7.56e-03	117	64	3	IPR013761
Domain	GPCR_Rhodpsn_7TM	OR4K17 OR4S2 OR6C2 OR52E6 OR4C46 OR4B1 OR8G2P	7.83e-03	670	64	7	IPR017452
Domain	Peptidase_M12B_N	ADAMDEC1 ADAMTS20	7.89e-03	39	64	2	IPR002870
Domain	Pep_M12B_propep	ADAMDEC1 ADAMTS20	7.89e-03	39	64	2	PF01562
Domain	TYR_PHOSPHATASE_PTP	PTPRB PTPN23	7.89e-03	39	64	2	PS50055
Domain	7tm_1	OR4K17 OR4S2 OR6C2 OR52E6 OR4C46 OR4B1 OR8G2P	8.26e-03	677	64	7	PF00001
Domain	DISINTEGRIN_1	ADAMDEC1 ADAMTS20	8.29e-03	40	64	2	PS00427
Domain	Reprolysin	ADAMDEC1 ADAMTS20	8.29e-03	40	64	2	PF01421
Domain	ADAM_MEPRO	ADAMDEC1 ADAMTS20	8.29e-03	40	64	2	PS50215
Domain	DISINTEGRIN_2	ADAMDEC1 ADAMTS20	8.29e-03	40	64	2	PS50214
Domain	Peptidase_M12B	ADAMDEC1 ADAMTS20	8.29e-03	40	64	2	IPR001590
Pubmed	The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense.	STK3 STK4 COL1A1	1.18e-07	6	64	3	23684612
Pubmed	Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis.	STK3 STK4 COL1A1	1.18e-07	6	64	3	25695629
Pubmed	Yap1 acts downstream of α-catenin to control epidermal proliferation.	STK3 STK4 COL1A1	3.31e-07	8	64	3	21376238
Pubmed	Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2.	STK3 STK4 COL1A1	9.70e-07	11	64	3	28486106
Pubmed	An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice.	STK3 STK4 COL1A1	2.66e-06	15	64	3	28457749
Pubmed	Regenerative Reprogramming of the Intestinal Stem Cell State via Hippo Signaling Suppresses Metastatic Colorectal Cancer.	STK3 STK4 COL1A1	3.27e-06	16	64	3	32730753
Pubmed	Systematic Interrogation of Cellular Signaling in Live Cells Using a Membrane-Anchored DNA Multitasking Processor.	MET VEGFA	3.33e-06	2	64	2	34990055
Pubmed	ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response.	ATF4 VEGFA	3.33e-06	2	64	2	18451308
Pubmed	Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer.	STK3 STK4	3.33e-06	2	64	2	34450249
Pubmed	MST1/2 in PDGFRα+ cells negatively regulates TGF-β-induced myofibroblast accumulation in renal fibrosis.	STK3 STK4	3.33e-06	2	64	2	35253468
Pubmed	Inactivation of MST1/2 Controls Macrophage Polarization to Affect Macrophage-Related Disease via YAP and Non-YAP Mechanisms.	STK3 STK4	3.33e-06	2	64	2	38250155
Pubmed	Effect of low-level laser therapy on the gene expression of collagen and vascular endothelial growth factor in a culture of fibroblast cells in mice.	COL1A1 VEGFA	3.33e-06	2	64	2	25171833
Pubmed	Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4.	ATF4 VEGFA	3.33e-06	2	64	2	14747470
Pubmed	STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.	STK3 STK4	3.33e-06	2	64	2	26457732
Pubmed	Expression analysis and essential role of the putative tyrosine phosphatase His-domain-containing protein tyrosine phosphatase (HD-PTP).	PTPN23 LASP1	3.33e-06	2	64	2	19378249
Pubmed	Position- and polarity-dependent Hippo signaling regulates cell fates in preimplantation mouse embryos.	STK3 STK4	3.33e-06	2	64	2	25986053
Pubmed	Hippo-YAP signaling controls lineage differentiation of mouse embryonic stem cells through modulating the formation of super-enhancers.	STK3 STK4	3.33e-06	2	64	2	32510157
Pubmed	Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.	STK3 STK4	3.33e-06	2	64	2	19878874
Pubmed	[Effect of proliferation, c-met and vascular endothelial growth factor expression in the Eca109/9706 cells by liposomal quercetin].	MET VEGFA	3.33e-06	2	64	2	19877526
Pubmed	Expression of ATF4 and VEGF in chorionic villus tissue in early spontaneous abortion.	ATF4 VEGFA	3.33e-06	2	64	2	23891064
Pubmed	Hippo pathway regulation by cell morphology and stress fibers.	STK3 STK4	3.33e-06	2	64	2	21831922
Pubmed	Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.	MET VEGFA	3.33e-06	2	64	2	20529820
Pubmed	Mammalian sterile 20 kinase 1 and 2 are important regulators of hematopoietic stem cells in stress condition.	STK3 STK4	3.33e-06	2	64	2	29343826
Pubmed	Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase.	MET PTPRB	3.33e-06	2	64	2	16101282
Pubmed	Biochemical markers of bone metabolism in breast cancer.	ALPL COL1A1	3.33e-06	2	64	2	25342482
Pubmed	Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling.	STK3 STK4	3.33e-06	2	64	2	19484742
Pubmed	Caspase-catalyzed cleavage and activation of Mst1 correlates with eosinophil but not neutrophil apoptosis.	STK3 STK4	3.33e-06	2	64	2	11964314
Pubmed	Effect of Inactivation of Mst1 and Mst2 in the Mouse Adrenal Cortex.	STK3 STK4	3.33e-06	2	64	2	36405866
Pubmed	STK3/STK4 signalling in adipocytes regulates mitophagy and energy expenditure.	STK3 STK4	3.33e-06	2	64	2	33758424
Pubmed	H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization.	STK3 STK4	3.33e-06	2	64	2	27238285
Pubmed	Glycation Contributes to Interaction Between Human Bone Alkaline Phosphatase and Collagen Type I.	ALPL COL1A1	3.33e-06	2	64	2	26645431
Pubmed	Newly identified stress-responsive protein kinases, Krs-1 and Krs-2.	STK3 STK4	3.33e-06	2	64	2	8816758
Pubmed	Cloning and characterization of a member of the MST subfamily of Ste20-like kinases.	STK3 STK4	3.33e-06	2	64	2	8566796
Pubmed	Association Study between SNPs in MST1 and MST2 and H. pylori Infection as well as Noncardia Gastric Carcinogenesis.	STK3 STK4	3.33e-06	2	64	2	38295774
Pubmed	Mammalian STE20-like kinase 2, not kinase 1, mediates photoreceptor cell death during retinal detachment.	STK3 STK4	3.33e-06	2	64	2	24874741
Pubmed	Loss of bone sialoprotein leads to impaired endochondral bone development and mineralization.	ALPL COL1A1 VEGFA	3.97e-06	17	64	3	25464126
Pubmed	Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.	STK3 STK4 MET ATF4 ADCY2 MAP3K5 VEGFA	5.47e-06	371	64	7	25241761
Pubmed	Site-1 protease regulates skeletal stem cell population and osteogenic differentiation in mice.	ALPL COL1A1 VEGFA	6.63e-06	20	64	3	29437042
Pubmed	Mst1/2 Is Necessary for Satellite Cell Differentiation to Promote Muscle Regeneration.	STK3 STK4	9.99e-06	3	64	2	35511870
Pubmed	Mammalian STE20-like kinase-1/2 are activated in human platelets stimulated by collagen or thrombin and play a vital role in collagen-activated platelets.	STK3 STK4	9.99e-06	3	64	2	36495715
Pubmed	RASSF2 associates with and stabilizes the proapoptotic kinase MST2.	STK3 STK4	9.99e-06	3	64	2	19525978
Pubmed	An aryl hydrocarbon receptor induces VEGF expression through ATF4 under glucose deprivation in HepG2.	ATF4 VEGFA	9.99e-06	3	64	2	24330582
Pubmed	Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance.	STK3 STK4	9.99e-06	3	64	2	22042863
Pubmed	Collagen regulates the ability of endothelial progenitor cells to protect hypoxic myocardium through a mechanism involving miR-377/VE-PTP axis.	PTPRB COL1A1	9.99e-06	3	64	2	30044046
Pubmed	Identification of ocular regulatory functions of core histone variant H3.2.	EPHA3 EPHA5	9.99e-06	3	64	2	36529279
Pubmed	Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma.	STK3 STK4	9.99e-06	3	64	2	17538946
Pubmed	The Mst1/2-BNIP3 axis is required for mitophagy induction and neuronal viability under mitochondrial stress.	STK3 STK4	9.99e-06	3	64	2	38443598
Pubmed	Mouse Hepatic Tumor Vascular Imaging by Experimental Selective Angiography.	STK3 STK4	9.99e-06	3	64	2	26131558
Pubmed	MST1/2 regulates fibro/adipogenic progenitor fate decisions in skeletal muscle regeneration.	STK3 STK4	9.99e-06	3	64	2	38552635
Pubmed	Harnessing Hippo in the heart: Hippo/Yap signaling and applications to heart regeneration and rejuvenation.	STK3 STK4	9.99e-06	3	64	2	24881775
Pubmed	Phosphorylation of LC3 by the Hippo kinases STK3/STK4 is essential for autophagy.	STK3 STK4	9.99e-06	3	64	2	25544559
Pubmed	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.	STK3 STK4	9.99e-06	3	64	2	25772357
Pubmed	Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity.	STK3 STK4	9.99e-06	3	64	2	19962960
Pubmed	Co-expression of VEGF, c-Met and HGF/SF in secondary pleural tumors.	MET VEGFA	9.99e-06	3	64	2	15492846
Pubmed	Hippo kinases MST1 and MST2 control the differentiation of the epididymal initial segment via the MEK-ERK pathway.	STK3 STK4	9.99e-06	3	64	2	32332916
Pubmed	Effects of individual control of pH and hypoxia in chondrocyte culture.	COL1A1 VEGFA	9.99e-06	3	64	2	19813243
Pubmed	Phosphorylation and dimerization regulate nucleocytoplasmic shuttling of mammalian STE20-like kinase (MST).	STK3 STK4	9.99e-06	3	64	2	11805089
Pubmed	MST1 limits the kinase activity of aurora B to promote stable kinetochore-microtubule attachment.	STK3 STK4	9.99e-06	3	64	2	20171103
Pubmed	Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependent mechanism: novel point of convergence between electrophilic and unfolded protein stress pathways.	ATF4 VEGFA	9.99e-06	3	64	2	20185790
Pubmed	A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span.	STK3 STK4	9.99e-06	3	64	2	16751106
Pubmed	Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway.	STK3 STK4	9.99e-06	3	64	2	28099921
Pubmed	Regulation of Protein Interactions by Mps One Binder (MOB1) Phosphorylation.	STK3 STK4	9.99e-06	3	64	2	28373297
Pubmed	MOB1 Mediated Phospho-recognition in the Core Mammalian Hippo Pathway.	STK3 STK4	9.99e-06	3	64	2	28373298
Pubmed	Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis.	STK3 STK4	9.99e-06	3	64	2	16510573
Pubmed	Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation.	STK3 STK4	9.99e-06	3	64	2	16930133
Pubmed	MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.	MET VEGFA	9.99e-06	3	64	2	26137585
Pubmed	Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease.	STK3 STK4	9.99e-06	3	64	2	24453252
Pubmed	EphrinA/EphA-induced ectodomain shedding of neural cell adhesion molecule regulates growth cone repulsion through ADAM10 metalloprotease.	EPHA3 EPHA5	9.99e-06	3	64	2	24117969
Pubmed	Cloning and characterization of a human protein kinase with homology to Ste20.	STK3 STK4	9.99e-06	3	64	2	7665586
Pubmed	The MST1/2-SAV1 complex of the Hippo pathway promotes ciliogenesis.	STK3 STK4	9.99e-06	3	64	2	25367221
Pubmed	The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2.	STK3 STK4	9.99e-06	3	64	2	21199877
Pubmed	Associations of VEGF/VEGF-receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity.	MET VEGFA	9.99e-06	3	64	2	23094709
Pubmed	Retinal pigment epithelium cells produce VEGF in response to oxidized phospholipids through mechanisms involving ATF4 and protein kinase CK2.	ATF4 VEGFA	9.99e-06	3	64	2	24021586
Pubmed	Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment.	STK3 STK4	9.99e-06	3	64	2	32470318
Pubmed	Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation.	STK3 STK4	9.99e-06	3	64	2	31434702
Pubmed	Regulation of MST complexes and activity via SARAH domain modifications.	STK3 STK4	9.99e-06	3	64	2	33860801
Pubmed	MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation.	STK3 STK4	9.99e-06	3	64	2	11278283
Pubmed	A MST1-FOXO1 cascade establishes endothelial tip cell polarity and facilitates sprouting angiogenesis.	STK3 STK4	9.99e-06	3	64	2	30783090
Pubmed	Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.	BRDT BRD3	9.99e-06	3	64	2	28945351
Pubmed	Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays.	MET VEGFA	9.99e-06	3	64	2	22395988
Pubmed	RNA Binding Protein RNPC1 Suppresses the Stemness of Human Endometrial Cancer Cells via Stabilizing MST1/2 mRNA.	STK3 STK4	9.99e-06	3	64	2	32088727
Pubmed	HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.	MET VEGFA	9.99e-06	3	64	2	23233163
Pubmed	Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade.	STK3 STK4 COL1A1	1.33e-05	25	64	3	30912742
Pubmed	The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.	STK3 STK4 MET MAP3K5	1.48e-05	80	64	4	28205554
Pubmed	Osteopotentia regulates osteoblast maturation, bone formation, and skeletal integrity in mice.	ATF4 ALPL COL1A1	1.68e-05	27	64	3	20440000
Pubmed	Dose-dependent effects of Runx2 on bone development.	ALPL COL1A1 VEGFA	1.88e-05	28	64	3	19419310
Pubmed	TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.	STK3 STK4	2.00e-05	4	64	2	28152516
Pubmed	Mammalian ste20-like kinase and SAV1 promote 3T3-L1 adipocyte differentiation by activation of PPARγ.	STK3 STK4	2.00e-05	4	64	2	22292086
Pubmed	MST1 deficiency promotes B cell responses by CD4+ T cell-derived IL-4, resulting in hypergammaglobulinemia.	STK3 STK4	2.00e-05	4	64	2	28527887
Pubmed	The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes.	STK3 STK4	2.00e-05	4	64	2	22412158
Pubmed	High-Molecular-Weight Hyaluronan Is a Hippo Pathway Ligand Directing Cell Density-Dependent Growth Inhibition via PAR1b.	STK3 STK4	2.00e-05	4	64	2	31080060
Pubmed	Smurf1 polyubiquitinates on K285/K282 of the kinases Mst1/2 to attenuate their tumor-suppressor functions.	STK3 STK4	2.00e-05	4	64	2	37890777
Pubmed	Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.	MET VEGFA	2.00e-05	4	64	2	20085644
Pubmed	YAP regulates alveolar epithelial cell differentiation and AGER via NFIB/KLF5/NKX2-1.	STK3 STK4	2.00e-05	4	64	2	34466790
Pubmed	FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.	STK3 STK4	2.00e-05	4	64	2	30903103
Pubmed	Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis.	STK3 STK4	2.00e-05	4	64	2	27869648
Pubmed	Mst1/2 Kinases Modulate Glucose Uptake for Osteoblast Differentiation and Bone Formation.	STK3 STK4	2.00e-05	4	64	2	29474739
Pubmed	Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.	MET VEGFA	2.00e-05	4	64	2	24016866
Pubmed	Two-signal requirement for growth-promoting function of Yap in hepatocytes.	STK3 STK4	2.00e-05	4	64	2	25667983
Pubmed	Disruption of ephrin signaling associates with disordered axophilic migration of the gonadotropin-releasing hormone neurons.	EPHA3 EPHA5	2.00e-05	4	64	2	15788771
Interaction	ZNF554 interactions	STK3 STK4 TRIM37	5.69e-06	12	61	3	int:ZNF554
Cytoband	Ensembl 112 genes in cytogenetic band chr9q34	SPTAN1 CERCAM BRD3 DBH CAMSAP1	9.34e-05	325	64	5	chr9q34
Cytoband	Ensembl 112 genes in cytogenetic band chr11q11	OR4S2 OR4C46	1.44e-03	40	64	2	chr11q11
Cytoband	9q34.11	SPTAN1 CERCAM	2.52e-03	53	64	2	9q34.11
Cytoband	9q34	BRD3 DBH	2.61e-03	54	64	2	9q34
GeneFamily	Olfactory receptors, family 4	OR4K17 OR4S2 OR4C46 OR4B1	2.69e-04	129	44	4	151
GeneFamily	Fibronectin type III domain containing\|Sterile alpha motif domain containing\|EPH receptors	EPHA3 EPHA5	5.17e-04	14	44	2	1095
Coexpression	SESTO_RESPONSE_TO_UV_C8	STK3 KIFAP3 GLG1 BRD3 VEGFA	7.86e-07	71	63	5	M2948
Coexpression	KANG_AR_TARGETS_DN	ALPL COL1A1 VEGFA	1.05e-05	18	63	3	MM892
Coexpression	KANG_AR_TARGETS_DN	ALPL COL1A1 VEGFA	1.05e-05	18	63	3	M2225
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HOMTN	KIFAP3 BACH2 DBH ST8SIA3 UNC79 ADCY2 EPHA3	4.07e-05	389	63	7	M39073
Coexpression	SCHLOSSER_SERUM_RESPONSE_DN	NCOA2 STK3 KIFAP3 ATF4 EIF3M ZFX MAP3K5 EPHA5 VEGFA	4.53e-05	705	63	9	M1410
Coexpression	BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN	STK3 BRDT LASP1	9.70e-05	37	63	3	MM785
Coexpression	BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN	STK3 BRDT LASP1	9.70e-05	37	63	3	M12678
Coexpression	GSE37416_CTRL_VS_48H_F_TULARENSIS_LVS_NEUTROPHIL_UP	KIFAP3 ACACB XAF1 EPHA5 ZC3HAV1	1.02e-04	193	63	5	M5339
Coexpression	MARTINEZ_RB1_AND_TP53_TARGETS_DN	BACH2 WDR12 BRD3 LASP1 MAP3K5 EPHA5 COL1A1 ITPR3	1.03e-04	610	63	8	M3854
Coexpression	RAMALHO_STEMNESS_UP	SOCS2 UTP20 PLA2G6 RPP14 ZFX	1.10e-04	196	63	5	M9473
Coexpression	GSE2706_2H_VS_8H_R848_AND_LPS_STIM_DC_DN	SOCS2 STK4 MET BACH2 XAF1	1.18e-04	199	63	5	M4738
Coexpression	GSE3982_DC_VS_MAC_LPS_STIM_DN	GCNT2 APOBEC3B ZFX EPHA5 ZC3HAV1	1.18e-04	199	63	5	M5390
Coexpression	GSE7764_IL15_NK_CELL_24H_VS_SPLENOCYTE_DN	STK4 BACH2 XAF1 RNF139 APOBEC3B	1.18e-04	199	63	5	M5726
Coexpression	GSE339_CD4POS_VS_CD4CD8DN_DC_IN_CULTURE_UP	NCOA2 PTPRB ELOVL1 UTP20 EPHA3	1.21e-04	200	63	5	M5122
Coexpression	RAMALHO_STEMNESS_UP	SOCS2 UTP20 PLA2G6 RPP14 ZFX	1.29e-04	203	63	5	MM1017
Coexpression	KIM_MYCN_AMPLIFICATION_TARGETS_DN	CCDC14 ADCY2 APOBEC3B COL1A1	1.30e-04	107	63	4	M2919
Coexpression	MARTINEZ_RB1_AND_TP53_TARGETS_DN	BACH2 WDR12 BRD3 LASP1 MAP3K5 EPHA5 COL1A1 ITPR3	1.60e-04	650	63	8	MM1042
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_k-means-cluster#2_top-relative-expression-ranked_1000	NCOA2 RGMB BACH2 ZNF565 CAMSAP1 ZFX EPHA3 VEGFA	1.76e-06	312	57	8	gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000_k2
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_1000	NCOA2 RGMB BACH2 ADAMTS20 LASP1 ZNF565 CAMSAP1 ZFX EPHA3 EPHA5 VEGFA	8.23e-06	806	57	11	gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000
CoexpressionAtlas	DevelopingKidney_e15.5_Pelvic Mesenchyme_emap-8241_top-relative-expression-ranked_1000	RGMB ADAMTS20 ZNF565 ADCY2 CLEC4C ZFX MAP3K5 EPHA3 COL1A1 VEGFA	5.19e-05	809	57	10	gudmap_developingKidney_e15.5_Pelvic Mesenchyme_1000
CoexpressionAtlas	dev gonad_e13.5_M_GermCell_Oct_top-relative-expression-ranked_1000	SOCS2 BRDT SPTAN1 UTP20 WDR12 TTC13 GCNT2 TRIM37 ALPL MAP3K5	5.24e-05	810	57	10	gudmap_dev gonad_e13.5_M_GermCell_Oct_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_top-relative-expression-ranked_1000	NCOA2 RGMB BACH2 ADAMTS20 LASP1 CAMSAP1 ZFX EPHA3 EPHA5 VEGFA	5.69e-05	818	57	10	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#4_top-relative-expression-ranked_1000	NCOA2 RGMB BACH2 CAMSAP1 ZFX EPHA3 VEGFA	7.39e-05	385	57	7	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000_k4
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k-means-cluster#1_top-relative-expression-ranked_100	RGMB ZFX EPHA3	1.23e-04	36	57	3	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k1_100
CoexpressionAtlas	DevelopingKidney_e15.5_Pelvic Mesenchyme_emap-8241_k-means-cluster#2_top-relative-expression-ranked_1000	ADAMTS20 ADCY2 CLEC4C MAP3K5 EPHA3 COL1A1	1.64e-04	305	57	6	gudmap_developingKidney_e15.5_Pelvic Mesenchyme_1000_k2
CoexpressionAtlas	dev gonad_e12.5_M_GermCellTestis_Oct_top-relative-expression-ranked_1000	CCDC14 SOCS2 BRDT UTP20 WDR12 TTC13 GCNT2 TRIM37 MAP3K5	2.48e-04	795	57	9	gudmap_dev gonad_e12.5_M_GermCellTestis_Oct_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_1000	SOCS2 MET AIG1 GCNT2 ADCY2 ALPL MAP3K5 EPHA3 EPHA5 COL1A1	2.59e-04	984	57	10	Facebase_RNAseq_e10.5_Olfactory Pit_1000
ToppCell	COPD-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	SOCS2 MET PTPRB ACACB VEGFA	8.14e-06	191	64	5	ef16ad1c1cd2c0c0377957398c98775b62a81754
ToppCell	facs-Aorta-Heart-3m-Mesenchymal\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET GLG1 CERCAM COL1A1 VEGFA	8.35e-06	192	64	5	0dc1f46e40346ed0b286e53b106a812441575100
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CCDC14 MET GCNT2 ALPL ITPR3	9.93e-06	199	64	5	2dc33804f6691d7c9682e6c9b885e945fb97fc36
Drug	1,1-dimethylbiguanide hydrochloride; Down 200; 10uM; MCF7; HG-U133A	STK3 ELOVL1 EXOC3 TTC13 EIF3M ITPR3 VEGFA	1.29e-06	196	64	7	2_DN
Drug	calcium silicate	ALPL COL1A1 VEGFA	1.40e-05	17	64	3	ctd:C031293
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	NCOA2 STK4 MET BACH2 SPTAN1 EPHA5	1.61e-05	191	64	6	4279_DN
Drug	Alfadolone acetate [23930-37-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A	STK3 KIFAP3 SPTAN1 EIF3M MAP3K5 ITPR3	1.87e-05	196	64	6	6506_DN
Drug	Benzthiazide [91-33-8]; Down 200; 9.2uM; MCF7; HT_HG-U133A	NCOA2 STK4 MET AIG1 ELOVL1 PLA2G6	1.87e-05	196	64	6	3329_DN
Drug	Homosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A	NCOA2 STK3 STK4 MET MAP3K5 COL1A1	1.92e-05	197	64	6	3797_DN
Drug	Sulconazole nitrate [61318-91-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A	STK3 MET GLG1 SPTAN1 AIG1 ATP9B	1.92e-05	197	64	6	4998_DN
Drug	Diclofenac sodium [15307-79-6]; Up 200; 12.6uM; MCF7; HT_HG-U133A	NCOA2 AIG1 XAF1 GCNT2 EPHA3 VEGFA	1.98e-05	198	64	6	2756_UP
Drug	(-)-MK 801 hydrogen maleate [77086-19-2]; Down 200; 11.8uM; HL60; HT_HG-U133A	STK3 SPTAN1 ATP9B CAMSAP1 ZFX ZC3HAV1	1.98e-05	198	64	6	3081_DN
Drug	Butacaine [149-16-6]; Up 200; 13uM; MCF7; HT_HG-U133A	NCOA2 SOCS2 SPTAN1 ZFX ITPR3 VEGFA	1.98e-05	198	64	6	3469_UP
Drug	Dichlorphenamide [120-97-8]; Up 200; 13.2uM; MCF7; HT_HG-U133A	NCOA2 STK4 GLG1 SPTAN1 ZFX VEGFA	2.03e-05	199	64	6	5286_UP
Drug	Paromomycin sulfate [1263-89-4]; Up 200; 5.6uM; PC3; HT_HG-U133A	MET PTPRB PLA2G6 GCNT2 ST8SIA3 ZFX	2.03e-05	199	64	6	4595_UP
Drug	2-aminoethoxydiphenyl borate	ATF4 COL1A1 ITPR3 VEGFA	2.63e-05	61	64	4	ctd:C109986
Drug	imatinib	SOCS2 KIFAP3 MET BACH2 EPHA3 EPHA5 COL1A1 VEGFA	2.66e-05	430	64	8	CID000005291
Drug	2-(1-cyclohexenyl)ethylamine	SOCS2 DBH	4.65e-05	4	64	2	CID000076938
Drug	Calcium Hydroxide	ALPL COL1A1	4.65e-05	4	64	2	ctd:D002126
Drug	Cocaine	MET PTPRB BACH2 SPTAN1 PLA2G6 ATP9B ATF4 DBH ADCY2 EPHA3 EPHA5 COL1A1 VEGFA	6.18e-05	1314	64	13	ctd:D003042
Drug	D2-1-2	PMS2 COL1A1	7.74e-05	5	64	2	CID003051453
Drug	AC1NRAEN	NCOA2 BRDT BRD3	8.15e-05	30	64	3	CID005287841
Drug	Calcium Chloride	LASP1 ALPL COL1A1 VEGFA	8.42e-05	82	64	4	ctd:D002122
Drug	Galactosamine	MET ATF4 COL1A1 VEGFA	8.83e-05	83	64	4	ctd:D005688
Drug	Nimodipine	NCOA2 DBH COL1A1	9.00e-05	31	64	3	ctd:D009553
Drug	Antigens, Polyomavirus Transforming	CCDC14 NCOA2 STK4 PMS2 BRD3 GCNT2 RNF139 ZFX ZC3HAV1	9.95e-05	668	64	9	ctd:D000952
Drug	26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3	NCOA2 ALPL	1.16e-04	6	64	2	ctd:C040488
Drug	beta-tyrosine	MET COL1A1 VEGFA	1.30e-04	35	64	3	CID000440311
Drug	fenvalerate	ALPL COL1A1 ITPR3 VEGFA	1.62e-04	97	64	4	ctd:C017690
Drug	carmustine; Up 200; 100uM; PC3; HT_HG-U133A	SOCS2 MET PMS2 EPHA5 ZC3HAV1	1.82e-04	187	64	5	6883_UP
Drug	18alpha-glycyrrhetinic acid	ALPL COL1A1 VEGFA	1.94e-04	40	64	3	ctd:C119129
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; PC3; HT_HG-U133A	NCOA2 STK4 MET PLA2G6 GCNT2	1.96e-04	190	64	5	4507_DN
Drug	Thioguanosine [85-31-4]; Up 200; 12.6uM; MCF7; HT_HG-U133A	GLG1 SPTAN1 CAMSAP1 COL1A1 VEGFA	1.96e-04	190	64	5	2619_UP
Drug	Dicumarol [66-76-2]; Up 200; 11.8uM; MCF7; HT_HG-U133A	ACACB CAMSAP1 ZFX EPHA3 COL1A1	1.96e-04	190	64	5	3848_UP
Drug	Harpagoside [19210-12-9]; Down 200; 8uM; MCF7; HT_HG-U133A	STK3 STK4 MET MAP3K5 VEGFA	2.01e-04	191	64	5	4981_DN
Drug	Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A	STK4 ACACB PLA2G6 COL1A1 VEGFA	2.01e-04	191	64	5	3605_DN
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; PC3; HT_HG-U133A	STK3 STK4 MET APOBEC3B ZFX	2.06e-04	192	64	5	4274_DN
Drug	Ergocryptine-alpha [511-09-1]; Up 200; 7uM; HL60; HT_HG-U133A	NCOA2 PTPRB SPTAN1 ATP9B VEGFA	2.06e-04	192	64	5	2572_UP
Drug	Zaprinast [37762-06-4]; Down 200; 14.8uM; PC3; HT_HG-U133A	PMS2 AIG1 ST8SIA3 COL1A1 VEGFA	2.11e-04	193	64	5	6749_DN
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	NCOA2 SOCS2 EPHA3 COL1A1 VEGFA	2.11e-04	193	64	5	7490_UP
Drug	Nilutamide [63612-50-0]; Down 200; 12.6uM; HL60; HT_HG-U133A	SOCS2 GLG1 PLA2G6 ATP9B CAMSAP1	2.11e-04	193	64	5	3104_DN
Drug	Doxycycline hydrochloride [10592-13-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A	MET GCNT2 EIF3M EPHA3 VEGFA	2.11e-04	193	64	5	3479_DN
Drug	O-C-O	ATF4 ALPL COL1A1 VEGFA	2.11e-04	104	64	4	CID000014785
Drug	2-Octen-1-al;	SOCS2 TRIM37	2.15e-04	8	64	2	CID000016900
Drug	Scopolamine hydrochloride [55-16-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	STK4 ACACB GCNT2 MAP3K5 EPHA5	2.16e-04	194	64	5	4219_DN
Drug	PHA-00745360 [351320-33-7]; Down 200; 10uM; PC3; HT_HG-U133A	STK4 ACACB GLG1 ZC3HAV1 COL1A1	2.16e-04	194	64	5	4559_DN
Drug	Flumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A	SOCS2 STK4 MET SPTAN1 ATP9B	2.16e-04	194	64	5	4272_DN
Drug	Niridazole [61-57-4]; Up 200; 18.6uM; MCF7; HT_HG-U133A	MET ACACB ZFX COL1A1 VEGFA	2.16e-04	194	64	5	3301_UP
Drug	ICI 182,780; Down 200; 1uM; PC3; HT_HG-U133A	STK4 PMS2 GLG1 SPTAN1 AIG1	2.16e-04	194	64	5	4429_DN
Drug	Ethoxyquin [91-53-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A	MET CAMSAP1 ADCY2 COL1A1 VEGFA	2.16e-04	194	64	5	3846_UP
Drug	Kainic Acid	SPTAN1 GCNT2 MAP3K5 COL1A1 VEGFA	2.16e-04	194	64	5	ctd:D007608
Drug	Gibberellic acid [77-06-5]; Down 200; 11.6uM; PC3; HT_HG-U133A	STK4 PTPRB SPTAN1 PLA2G6 ZFX	2.22e-04	195	64	5	4234_DN
Drug	Benzocaine [94-09-7]; Down 200; 24.2uM; PC3; HT_HG-U133A	SPTAN1 PLA2G6 MAP3K5 EPHA5 COL1A1	2.22e-04	195	64	5	4224_DN
Drug	Bambuterol hydrochloride [81732-46-9]; Up 200; 10uM; PC3; HT_HG-U133A	SOCS2 PTPRB BACH2 CAMSAP1 MAP3K5	2.22e-04	195	64	5	5885_UP
Drug	PHA-00767505E [723337-45-9]; Up 200; 10uM; PC3; HT_HG-U133A	STK3 MET PMS2 AIG1 GCNT2	2.22e-04	195	64	5	6545_UP
Drug	salubrinal	ATF4 MAP3K5 VEGFA	2.25e-04	42	64	3	ctd:C496827
Drug	Allantoin [97-59-6]; Down 200; 25.2uM; PC3; HT_HG-U133A	NCOA2 STK4 ACACB SPTAN1 VEGFA	2.27e-04	196	64	5	5052_DN
Drug	Hymecromone [90-33-5]; Up 200; 22.8uM; PC3; HT_HG-U133A	NCOA2 PLA2G6 EPHA3 EPHA5 COL1A1	2.27e-04	196	64	5	4623_UP
Drug	Iocetamic acid [16034-77-8]; Up 200; 6.6uM; PC3; HT_HG-U133A	NCOA2 MET PLA2G6 XAF1 ZFX	2.27e-04	196	64	5	4600_UP
Drug	(1)-Nipecotic acid [498-95-3]; Down 200; 31uM; HL60; HT_HG-U133A	STK3 PLA2G6 ATP9B CAMSAP1 ZC3HAV1	2.27e-04	196	64	5	3121_DN
Drug	Benzamil hydrochloride [2898-76-2]; Up 200; 11.2uM; PC3; HT_HG-U133A	NCOA2 SPTAN1 ADCY2 MAP3K5 ITPR3	2.27e-04	196	64	5	3738_UP
Drug	PHA-00767505E [723337-45-9]; Down 200; 10uM; PC3; HT_HG-U133A	ACACB BACH2 SPTAN1 GCNT2 ZC3HAV1	2.27e-04	196	64	5	6591_DN
Drug	Sulfinpyrazone [57-96-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A	STK3 MET ACACB PLA2G6 COL1A1	2.27e-04	196	64	5	3192_DN
Drug	Midecamycin [35457-80-8]; Down 200; 5uM; PC3; HT_HG-U133A	STK4 ACACB SPTAN1 ST8SIA3 ZFX	2.27e-04	196	64	5	6745_DN
Drug	Chlorogenic acid [327-97-9]; Up 200; 11.2uM; HL60; HT_HG-U133A	PMS2 ATP9B EIF3M ZFX VEGFA	2.27e-04	196	64	5	1346_UP
Drug	Drugs, Chinese Herbal	NCOA2 MET XAF1 ZFX MAP3K5 ZC3HAV1 COL1A1 VEGFA	2.29e-04	586	64	8	ctd:D004365
Drug	Chlorogenic acid [327-97-9]; Up 200; 11.2uM; PC3; HT_HG-U133A	STK4 AIG1 ADAMTS20 ATP9B EPHA5	2.32e-04	197	64	5	4024_UP
Drug	CP-320650-01 [172079-28-6]; Down 200; 1uM; PC3; HT_HG-U133A	PTPRB ADAMTS20 PLA2G6 ATP9B GCNT2	2.32e-04	197	64	5	3825_DN
Drug	Meprylcaine hydrochloride [956-03-6]; Down 200; 14.8uM; MCF7; HT_HG-U133A	MET PMS2 ATP9B ITPR3 VEGFA	2.32e-04	197	64	5	3544_DN
Drug	3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; HL60; HT_HG-U133A	SOCS2 STK4 GLG1 GCNT2 ST8SIA3	2.32e-04	197	64	5	3044_DN
Drug	Demecarium bromide [56-94-0]; Up 200; 5.6uM; MCF7; HT_HG-U133A	MET ACACB CAMSAP1 COL1A1 VEGFA	2.32e-04	197	64	5	2773_UP
Drug	Molsidomine [25717-80-0]; Down 200; 16.6uM; HL60; HG-U133A	MET PMS2 SPTAN1 XAF1 EIF3M	2.32e-04	197	64	5	1711_DN
Drug	Coralyne chloride hydrate [38989-38-7]; Down 200; 9.6uM; PC3; HT_HG-U133A	NCOA2 STK4 BACH2 ZC3HAV1 VEGFA	2.32e-04	197	64	5	6317_DN
Drug	Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A	STK3 SPTAN1 ADAMTS20 COL1A1 VEGFA	2.32e-04	197	64	5	2654_UP
Drug	Streptomycin sulfate [3810-74-0]; Down 200; 2.8uM; MCF7; HT_HG-U133A	ACACB PLA2G6 CAMSAP1 COL1A1 VEGFA	2.32e-04	197	64	5	3195_DN
Drug	Beta-Escin [11072-93-8]; Down 200; 3.2uM; MCF7; HT_HG-U133A	MET ACACB SPTAN1 AIG1 COL1A1	2.32e-04	197	64	5	6050_DN
Drug	Hecogenin [467-55-0]; Down 200; 9.2uM; PC3; HT_HG-U133A	MET ACACB SPTAN1 ELOVL1 VEGFA	2.32e-04	197	64	5	5818_DN
Drug	Medrysone [2668-66-8]; Down 200; 11.6uM; PC3; HT_HG-U133A	SOCS2 STK4 MET GLG1 APOBEC3B	2.32e-04	197	64	5	4266_DN
Drug	Flunisolide [3385-03-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	ACACB SPTAN1 PLA2G6 ZFX COL1A1	2.38e-04	198	64	5	6023_DN
Drug	Ticarcillin sodium [4697-14-7]; Up 200; 9.4uM; PC3; HT_HG-U133A	STK4 ACACB AIG1 PLA2G6 GCNT2	2.38e-04	198	64	5	5829_UP
Drug	Oxaprozin [21256-18-8]; Up 200; 13.6uM; PC3; HT_HG-U133A	NCOA2 ACACB CAMSAP1 ADCY2 ZFX	2.38e-04	198	64	5	4530_UP
Drug	Altretamine [654-05-6]; Down 200; 19uM; PC3; HT_HG-U133A	PTPRB SPTAN1 GCNT2 MAP3K5 COL1A1	2.38e-04	198	64	5	4627_DN
Drug	Remoxipride Hydrochloride [73220-03-8]; Up 200; 9.8uM; MCF7; HT_HG-U133A	PTPRB ACACB GLG1 CAMSAP1 EPHA3	2.38e-04	198	64	5	6503_UP
Drug	Theobromine [83-67-0]; Down 200; 22.2uM; HL60; HT_HG-U133A	SOCS2 PTPRB SPTAN1 PLA2G6 EPHA3	2.38e-04	198	64	5	2995_DN
Drug	Doxepin hydrochloride [1229-29-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A	STK3 MET EIF3M ITPR3 VEGFA	2.38e-04	198	64	5	7415_DN
Drug	trifluoperazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A_EA	NCOA2 MET SPTAN1 CAMSAP1 MAP3K5	2.38e-04	198	64	5	1004_DN
Drug	Avermectin B1 [71751-41-2]; Up 200; 4.8uM; HL60; HT_HG-U133A	STK3 PTPRB SPTAN1 ATP9B APOBEC3B	2.38e-04	198	64	5	2519_UP
Drug	Suprofen [40828-46-4]; Up 200; 15.4uM; HL60; HT_HG-U133A	STK3 MET DBH ST8SIA3 COL1A1	2.38e-04	198	64	5	3005_UP
Drug	Ethamivan [304-84-7]; Down 200; 18uM; MCF7; HT_HG-U133A	SPTAN1 AIG1 CAMSAP1 ZFX VEGFA	2.38e-04	198	64	5	2879_DN
Drug	Antimycin A [1397-94-0]; Up 200; 7.2uM; PC3; HT_HG-U133A	PTPRB AIG1 ADAMTS20 COL1A1 ITPR3	2.38e-04	198	64	5	5053_UP
Drug	Trazodone hydrochloride [25332-39-2]; Up 200; 9.8uM; HL60; HT_HG-U133A	NCOA2 PLA2G6 GCNT2 CAMSAP1 ITPR3	2.38e-04	198	64	5	2379_UP
Drug	estradiol; Up 200; 0.01uM; MCF7; HT_HG-U133A	MET ADAMDEC1 ATP9B XAF1 ITPR3	2.38e-04	198	64	5	5905_UP
Drug	Ribostamycin sulfate salt [53797-35-6]; Down 200; 7.2uM; MCF7; HT_HG-U133A	ACACB SPTAN1 CAMSAP1 ZC3HAV1 COL1A1	2.43e-04	199	64	5	6765_DN
Drug	Rifampicin [13292-46-1]; Up 200; 4.8uM; PC3; HT_HG-U133A	GLG1 SPTAN1 PLA2G6 CAMSAP1 EPHA5	2.43e-04	199	64	5	4008_UP
Drug	Molsidomine [25717-80-0]; Down 200; 16.6uM; MCF7; HT_HG-U133A	SOCS2 AIG1 ZC3HAV1 COL1A1 VEGFA	2.43e-04	199	64	5	5426_DN
Drug	Spectinomycin dihydrochloride [21736-83-4]; Down 200; 9.8uM; HL60; HT_HG-U133A	NCOA2 STK4 SPTAN1 UTP20 PLA2G6	2.43e-04	199	64	5	2987_DN
Drug	aspirin, USP; Down 200; 100uM; MCF7; HG-U133A	KIFAP3 SPTAN1 XAF1 CAMSAP1 VEGFA	2.43e-04	199	64	5	315_DN
Drug	genistein; Down 200; 10uM; MCF7; HT_HG-U133A	SOCS2 SPTAN1 ATP9B EPHA3 ZC3HAV1	2.43e-04	199	64	5	1660_DN
Drug	Benoxinate hydrochloride [5987-82-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A	NCOA2 MET APOBEC3B EIF3M VEGFA	2.49e-04	200	64	5	1476_DN
Drug	Carbamazepine [298-46-4]; Up 200; 17uM; MCF7; HT_HG-U133A	NCOA2 PLA2G6 XAF1 EIF3M COL1A1	2.49e-04	200	64	5	1683_UP
Drug	Butamben [94-25-7]; Up 200; 20.6uM; MCF7; HT_HG-U133A	NCOA2 GLG1 SPTAN1 AIG1 MAP3K5	2.49e-04	200	64	5	6266_UP
Drug	cyclopropyl	NCOA2 SOCS2 BRD3	2.76e-04	45	64	3	CID000123162
Drug	GalCer	TRIM37 ALPL	2.76e-04	9	64	2	CID006321355
Disease	brain glioma (is_marker_for)	PTPRB VEGFA	4.33e-05	5	62	2	DOID:0060108 (is_marker_for)
Disease	Malignant Neoplasms	MET APOBEC3B EPHA3 VEGFA	1.55e-04	128	62	4	C0006826
Disease	Pancreatic Ductal Adenocarcinoma	ACACB EPHA3	2.36e-04	11	62	2	C1335302
Disease	liver benign neoplasm (biomarker_via_orthology)	MET COL1A1	2.36e-04	11	62	2	DOID:916 (biomarker_via_orthology)
Disease	phosphocreatine measurement	ADAMTS20 ALPL	3.34e-04	13	62	2	EFO_0010521
Disease	Rhabdomyosarcoma	PMS2 VEGFA	4.48e-04	15	62	2	C0035412
Disease	empathy measurement	BACH2 ADAMTS20 UNC79 MAP3K5	4.57e-04	170	62	4	EFO_0009183
Disease	Endometrial Carcinoma	PMS2 LASP1 VEGFA	4.75e-04	72	62	3	C0476089
Disease	central corneal thickness	STK4 ADAMTS20 EXOC3 BRD3 COL1A1	4.84e-04	309	62	5	EFO_0005213
Disease	Bipolar Disorder	STK4 PLA2G6 ATF4 DBH ADCY2 VEGFA	4.95e-04	477	62	6	C0005586
Disease	Hemangiosarcoma	PTPRB VEGFA	6.50e-04	18	62	2	C0018923
Disease	triglyceride measurement, body fat percentage	PLA2G6 VEGFA	8.89e-04	21	62	2	EFO_0004530, EFO_0007800
Disease	colorectal carcinoma (is_implicated_in)	NCOA2 PTPRB	9.77e-04	22	62	2	DOID:0080199 (is_implicated_in)
Disease	portal hypertension (biomarker_via_orthology)	DBH VEGFA	9.77e-04	22	62	2	DOID:10762 (biomarker_via_orthology)
Disease	obesity (implicated_via_orthology)	STK3 STK4 ADAMTS20 ITPR3	1.10e-03	215	62	4	DOID:9970 (implicated_via_orthology)
Disease	Head Neoplasms	APOBEC3B VEGFA	1.16e-03	24	62	2	C0018675
Disease	Upper Aerodigestive Tract Neoplasms	APOBEC3B VEGFA	1.16e-03	24	62	2	C0887900
Disease	Cancer of Head	APOBEC3B VEGFA	1.16e-03	24	62	2	C0751177
Disease	Neck Neoplasms	APOBEC3B VEGFA	1.26e-03	25	62	2	C0027533
Disease	Cancer of Neck	APOBEC3B VEGFA	1.26e-03	25	62	2	C0746787
Disease	body fat percentage, high density lipoprotein cholesterol measurement	PLA2G6 VEGFA	1.26e-03	25	62	2	EFO_0004612, EFO_0007800
Disease	primary biliary cholangitis (biomarker_via_orthology)	COL1A1 VEGFA	1.59e-03	28	62	2	DOID:12236 (biomarker_via_orthology)
Disease	arteriosclerosis (is_marker_for)	MET ALPL	1.70e-03	29	62	2	DOID:2349 (is_marker_for)
Disease	Large cell carcinoma of lung	EPHA3 EPHA5	2.07e-03	32	62	2	C0345958
Disease	Squamous cell carcinoma of lung	EPHA3 EPHA5	2.07e-03	32	62	2	C0149782

Protein segments in the cluster

Peptide	Gene	Start	Entry
MYNQVRPQIKCEQSY	BACH2	571	Q9BYV9
NCYKYNPPDHEVVAM	BRD3	386	Q15059
LCNYKAIEMPSHQTY	AIG1	21	Q9NVV5
RGQVYFKPQYHAEMC	APOBEC3B	56	Q9UH17
MNCYKYNPPDHEVVT	BRDT	346	Q58F21
DYTAYVAMIPQCIKE	ATF4	196	P18848
ENYAPIHTYQVCKVM	EPHA5	91	P54756
AVIHYYCPEQMKLDD	CAMSAP1	256	Q5T5Y3
MYSPIIYQALCEHVQ	CCDC14	201	Q49A88
QVLCMNYHQPIDENY	ADAMTS20	1231	P59510
YVAICKPLHYVVIMN	OR6C2	121	Q9NZP2
CYSLKNRHQDVMPYD	PTPN23	1216	Q9H3S7
ITEVKMAYVNFVNHC	ITPR3	1406	Q14573
EKNIISYPECMTQLY	OR8G2P	101	Q6IF36
VLPTFFYHANKVVCM	ACACB	1276	O00763
MVQTECQYVYLHQCV	PTPRB	1946	P23467
AIYMPQNVYCVHLDQ	GCNT2	116	Q8N0V5
ISAYVYAQKPQMDIH	ATP9B	296	O43861
HGMDKNTPVRYTVYC	EIF3M	111	Q7L2H7
PYCNAHYPKQSFTMV	LASP1	51	Q14847
MCLQVAIAALYYNPH	IPO7	781	O95373
YVAICKPLHYMTIMN	OR4C46	121	A6NHA9
IQTEQSLHEPMYYCL	OR52E6	51	Q96RD3
YVAICKPLHYMTIMN	OR4K17	126	Q8NGC6
YVAICKPLHYMTIMN	OR4S2	121	Q8NH73
EQNYVPHVMAYAACI	ALPL	476	P05186
ITEYQCHQYITKMTA	GLG1	211	Q92896
SYYCMSQQHPLIVFL	ADCY2	36	Q08462
EMCVNYVHYYPQTQL	DBH	486	P09172
FMSSCNYQYPVIIHL	ELOVL1	221	Q9BW60
HYTPIRTYQVCNVMD	EPHA3	61	P29320
QHPHCYVQYMIAIIN	EXOC3	481	O60645
VCNEHRYGYMNVPVK	CERCAM	261	Q5T4B2
NDNYKQIAMCVLYHI	KIFAP3	396	Q92845
YVAICKPLHYMNIIS	OR4B1	121	Q8NGF8
TFVPYMITPHNKVYC	MAP3K5	211	Q99683
LYIQDTCPMCHQKVY	RNF139	576	Q8WU17
HVNATYVNVKCVAPY	MET	1351	P08581
VDVNYLIPVMHNCFY	UTP20	1466	O75691
TQCHEKMPVKDIYFQ	RGMB	356	Q6NW40
YEYRVEMVHQSCNDP	TRIM37	341	O94972
SVVHLIDYYVQMCKD	SOCS2	121	O14508
VSPIMNKHYNICAVV	ST8SIA3	151	O43173
LVQYCHTQMDVTDYK	PLA2G6	171	O60733
TKPENMEHCYYKGNI	ADAMDEC1	116	O15204
YQQYHPSLTCVMEGK	CLEC4C	61	Q8WTT0
ITYHCKNSVAYMDQQ	COL1A1	1366	P02452
HQKYETMQCFAVSQP	NCOA2	221	Q15596
ISIMQQCDSPYVVKY	STK3	71	Q13188
EPYNEVCQYMKGLSH	TTC13	381	Q8NBP0
EECYFKQVNVTYGHM	ZNF565	171	Q8N9K5
EQYPCQTKVAAAIMH	UROC1	91	Q96N76
EQADYCVSHMKPYVD	SPTAN1	2436	Q13813
IYCHYCNQMIPENKY	XAF1	151	Q6GPH4
MGVSVDVHQVYKYPF	PRELID2	1	Q8N945
HMIPEHQYQTYKNLC	ZC3H12B	786	Q5HYM0
YAKMVQVLHAYCIIS	PMS2	181	P54278
HMRIHTGEKPYQCQY	ZFX	566	P17010
IMQQCDSPHVVKYYG	STK4	76	Q13043
YSHKNCPYDAKNVVM	ZC3HAV1	826	Q7Z2W4
CPYDAKNVVMFVAQV	ZC3HAV1	831	Q7Z2W4
VEKYTAPQPEQCMFH	WDR12	86	Q9GZL7
VKFMDVYQRSYCHPI	VEGFA	41	P15692
VVYKNPSEYHYMKVC	RPP14	11	O95059
MQYTSNPVYHCQLLE	UNC79	231	Q9P2D8